Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB)
|
Add to portfolio |
|
|
|
| Price: |
$1.69
| | Metrics |
| OS: |
99.8
|
M
| |
|
|
| Market cap: |
$169
|
M
| |
|
|
|
Net cash:
|
$4.82
|
M
| |
$0.05
|
per share
|
|
EV:
|
$164
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($12.9)
|
M
| |
|
|
|
EBIT
|
($13.0)
|
M
| |
|
|
| EPS |
($0.44)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.1 | 0.5 | 0.9 | 0.7 | 1.2 | 1.8 | 5.0 | 3.0 |
| Revenue growth | -87.6% | -41.9% | 39.1% | -43.7% | -35.4% | -63.6% | 65.0% | -52.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 |
| Gross profit | 0.1 | 0.5 | 0.9 | 0.7 | 1.1 | 1.8 | 4.9 | 3.0 |
| Gross margin | 97.0% | 100.0% | 99.9% | 99.0% | 91.7% | 99.8% | 98.7% | 99.9% |
| Selling, general and administrative | 8.0 | 7.5 | 6.7 | 6.3 | 7.7 | 11.2 | 7.9 | 10.9 |
| Research and development | 6.0 | 5.1 | 4.9 | 5.3 | 4.2 | 4.5 | 7.1 | 10.6 |
| EBITA | -14.0 | -12.0 | -10.7 | -10.9 | -10.8 | -13.9 | -10.2 | -18.7 |
| EBITA margin | -21329.6% | -2261.5% | -1166.6% | -1660.2% | -925.1% | -765.3% | -204.3% | -621.8% |
| Amortization of intangibles | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT | -14.1 | -12.1 | -10.7 | -11.0 | -10.8 | -13.9 | -10.2 | -18.7 |
| EBIT margin | -21402.1% | -2269.1% | -1170.6% | -1666.5% | -927.6% | -766.5% | -204.4% | -622.1% |
| Pre-tax income | -15.2 | -11.7 | -10.7 | -10.9 | -16.2 | -17.8 | -7.4 | -23.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.1 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 0.0% | | 0.1% | 22.8% | 0.0% | 0.0% |
| Earnings from continuing ops | -17.2 | -11.7 | -11.4 | -10.9 | -16.2 | -14.2 | -14.3 | -27.6 |
| Earnings from discontinued ops | | | | 0.0 | 0.0 | 89.2 | | |
| Net income | -17.2 | -11.7 | -11.4 | -10.9 | -16.1 | 74.9 | -14.3 | -27.6 |
| Net margin | -26221.7% | -2207.1% | -1244.3% | -1664.3% | -1378.0% | 4139.7% | -287.8% | -916.2% |
| |
| Diluted EPS | ($0.56) | ($0.40) | ($0.48) | ($0.76) | ($1.90) | ($0.09) | ($0.09) | ($0.18) |
| Shares outstanding (diluted) | 30.9 | 29.3 | 23.9 | 14.4 | 8.5 | 166.0 | 155.4 | 151.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|